SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.040
-0.020 (-0.65%)
Nov 21, 2024, 12:56 PM EST - Market open
SAB Biotherapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for SAB Biotherapeutics stock have an average target of 12.4, with a low estimate of 6.00 and a high estimate of 25. The average target predicts an increase of 307.89% from the current stock price of 3.04.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for SABS stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +722.37% | Nov 7, 2024 |
| Craig-Hallum | Craig-Hallum | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +261.84% | Oct 9, 2024 |
| Oppenheimer | Oppenheimer | Buy Reiterates $12 | Buy | Reiterates | $12 | +294.74% | Sep 12, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +722.37% | Sep 9, 2024 |
| Oppenheimer | Oppenheimer | Buy Initiates $12 | Buy | Initiates | $12 | +294.74% | Aug 28, 2024 |
Financial Forecast
Revenue This Year
1.41M
from 2.24M
Decreased by -37.07%
Revenue Next Year
1.02M
from 1.41M
Decreased by -27.61%
EPS This Year
-3.71
from -7.64
EPS Next Year
-2.91
from -3.71
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 1.8M | 2.1M | 3.2M | ||
| Avg | 1.4M | 1.0M | 1.3M | ||
| Low | 1.2M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -20.3% | 49.0% | 208.8% | ||
| Avg | -37.1% | -27.6% | 25.0% | ||
| Low | -47.1% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -3.72 | -1.02 | -1.04 |
| Avg | -3.71 | -2.91 | -2.69 |
| Low | -3.68 | -5.16 | -3.93 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.